Gilead Sciences Inc. on Thursday said its Kite unit signed a collaboration and license agreement with biotechnology startup Appia Bio Inc. to research and develop allogeneic cell therapies for cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,